Page 134 - Eceptor News Today

Researchers identified drugs inhibiting the entry of SARS-CoV-2.

In a new study, different signal peptides, baculovirus transfer vectors, cell lines, infection techniques, and formulation buffers were investigated with the purpose of building a scalable bioprocess to generate high-quality S protein for incorporation in a virosome-based COVID-19 vaccine candidate.

Gut microbiota by-products circulate in the bloodstream, regulating host physiological processes including immunity, metabolism and brain functions.

A new study examined the serological immune responses and antibody-dependent cell-mediated phagocytosis in individuals who had either received two doses of a standard vaccine regime, a booster dose following the regime, or a breakthrough infection following vaccination.

Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer.

A new study compares the SARS-CoV-2 RBD to the SARS-CoV RBD using computational methods to understand their binding affinities to ACE2.

Researchers at Mayo Clinic's Center for Individualized Medicine have devised an immunotherapy technique that combines chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, with a cancer-killing virus to more effectively target and treat solid cancer tumors.

In a recent study, researchers assessed the anti-COVID-19 efficacy of Salvia miltiorrhiza Bunge.

Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the AACR Annual Meeting 2022, held April 8-13.

Researchers discussed and identified the systemic functions and interactions of 52 active cell surface receptor tyrosine kinases, providing insights on RTK-RTK interactions and substrates, RTK-protein complexes, and signaling pathways.